566
Participants
Start Date
October 31, 2025
Primary Completion Date
May 31, 2028
Study Completion Date
December 31, 2028
TQB2868 Injection
TQB2868 injection: PD-L1 and Transforming Growth Factor-beta (TGF - β) dual antibody
Anlotinib Hydrochloride Capsules
Anlotinib Hydrochloride Capsules
Gemcitabine Hydrochloride Injection
Gemcitabine Hydrochloride Injection
Paclitaxel for Injection
Paclitaxel for Injection
TQB2868 Placebo
TQB2868 Placebo without drug substance
Peking University Cancer Hospital Inner Mongolia Hospital, Hohhot
Peking University First Hospital, Beijing
Beijing Friendship Hospital,Capital Medical University, Beijing
The Fifth Medical Center of Chinese People's Liberation Army General Hospital, Beijing
Beijing Daxing District People'S Hospital, Beijing
Liaoning Cancer Hospital, Shenyang
The First Hospital of China Medical University, Shenyang
Jilin Cancer Hospital, Changchun
The first hospital of Jilin University, Changchun
Harbin Medical University Cancer Hospital, Haerbin
Daqing Oilfield General Hospital, Daqing
Fudan University Shanghai Cancer Center, Shanghai
Shanghai Sixth People's Hospital, Shanghai
Shanghai General Hospital, Shanghai
Jiangsu Province Hospital, Nanjing
Jiangyin People'S Hospital, Jiangyin
The First Affiliated Hospital of Soochow University, Suzhou
The Affiliated Hospital of Xuzhou Medical University, Xuzhou
Nantong Tumor Hospital, Nantong
The First Affiliated Hospital of USTC Anhui Provincial Hospital, Hefei
Anhui Provincial Cancer Hospital, Hefei
Qilu Hospital of Shandong University, Jinan
The Affiliated Hospital Of Medical College Qingdao University, Qingdao
Linyi people's hospital, Linyi
Linyi Cancer Hospital, Liyi
Tianjin Cancer Hospital Airport Hospital, Tianjin
Tianjin Medical University Cancer Institute & Hospital, Tianjin
The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou
Sir Run Run Shaw Hospital , affiliated with the Zhejiang University School of Medicine, Hangzhou
Shaoxing People's Hospital, Shaoxing
Ningbo Medical Center Lihuili Hospital, Ningbo
Wenzhou Medical University Affiliated First Hospital, Wenzhou
The First Affiliated Hospital of Nanchang University, Nanchang
Mengchao Hepatobiliary Hospital OF Fujian Medical University, Fuzhou
The Firstaffiliated Hospital of Xiamen University, Xiamen
Zhongshan Hospital Xiamen University, Xiamen
The First Affiliated Hospital of Chongqing Medical University, Chongqing
Hunan Cancer Hospital, Changsha
People's Hospital of Hunan Province, Changsha
Zhongnan Hospital of Wuhan University, Wuhan
Hubei Cancer Hospital, Wuhan
Xiangyang Central Hospital, Xiangyang
Henan Cancer Hospital, Zhengzhou
The First Affiliated Hospital of Zhengzhou University, Zhengzhou
The First Affiliated Hospital of Henan University of Science & Technology, Luoyang
Sun Yat-Sen University, Guangzhou
The First Affiliated Hospital of Guangzhou Medical University, Guangzhou
Sun Yat-Sen University Cancer Center, Guangzhou
Guangxi Cancer Institute, Nanning
Guizhou Medical University Affiliated Cancer Hospital Co., LTD, Guiyang
Affiliated Hospital of Zunyi Medical Universityl, Zunyi
Hainan general hospital, Haikou
Sichuan Cancer Hospital, Chengdu
Affiliated Hospital of North Sichuan Medical College, Nanchong
The Affiliated Hospital of Southwest Medical University, Luzhou
Yunnan Cancer Hospital, Kunming
The Second Affiliated Hospital of PLA Air Force Military Medical University, Xi'an
The First Affiliated Hospital of Xi 'An Jiaotong University, Xi'an
Gansu Provincial Hospital, Lanzhou
The First Hospital of Lanzhou University, Lanzhou
Lanzhou University Second Hospital, Lanzhou
People's Hospital of Xinjiang Uygur Autonomous Region, Ürümqi
Cancer Hospital Chinese Academy pf Medical Sciences, Langfang
Tangshan peopel's Hospital, Tangshan
Shanxi Cancer Hospital, Taiyuan
First Hospital of Shanxi Medical University, Taiyuan
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
INDUSTRY